Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 62/488,366, filed Apr 21, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,894,804 | Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus In force · Low confidence UsedRemaining | Atea Pharmaceuticals, Inc. | In force | Low confidence | ||
| US 10,906,928 | Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus In force · Low confidence | Atea Pharmaceuticals, Inc. | In force | Low confidence | ||
| US 12,006,340 | Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus In force · Medium confidence | Atea Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 12,741,984 | Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,519,186 | Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| Application 17/118,314 | Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus Abandoned Abandoned Jun 18, 2022 | Atea Pharmaceuticals, Inc. | Abandoned | Abandoned Jun 18, 2022 | ||
| Application 17/306,659 | Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus Abandoned Abandoned Jan 28, 2023 | Atea Pharmaceuticals, Inc. | Abandoned | Abandoned Jan 28, 2023 |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Atea Pharmaceuticals, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.